Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to -$1.0 million.

  • Ultragenyx Pharmaceutical's Non Operating Income fell 13389.67% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 19916.96%. This contributed to the annual value of -$4.0 million for FY2024, which is 107596.44% down from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Non Operating Income stood at -$1.0 million for Q3 2025, which was down 13389.67% from $2.1 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Non Operating Income peaked at $3.1 million during Q3 2024, and registered a low of -$3.6 million during Q4 2024.
  • Moreover, its 5-year median value for Non Operating Income was -$415000.0 (2021), whereas its average is -$295736.8.
  • Its Non Operating Income has fluctuated over the past 5 years, first crashed by 128805.97% in 2022, then skyrocketed by 103500.0% in 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Non Operating Income (Quarter) stood at -$410000.0 in 2021, then surged by 143.9% to $180000.0 in 2022, then surged by 1035.0% to $2.0 million in 2023, then plummeted by 276.51% to -$3.6 million in 2024, then skyrocketed by 71.08% to -$1.0 million in 2025.
  • Its Non Operating Income was -$1.0 million in Q3 2025, compared to $2.1 million in Q2 2025 and $837000.0 in Q1 2025.